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EDITORIALS 
Does Thrombolytic Therapy Reduce Infarct Size?* 
ARTHUR SELZER, MD 
Myocardial damage and the resulting pump failure represent 
a fundamental mechanism for death and disability in acute 
myocardial infarction. For decades investigators considered 
the feasibility of myocardial salvage by reducing infarct size 
(I). The development of effective thrombolytic therapy and 
the results of the early studies suggesting the possibility that 
mortality from acute myocardial infarction may be reduced 
have aroused great enthusiasm. The results were interpreted 
as showing that an effective method for reducing infarct size 
has finally been found. This hypothesis is now universally 
accepted. Yet, a critical review of the evidence supporting 
this hypothesis raises many questions. 
It is generally accepted that myocardial ischemia due to 
total cessation of coronary blood supply becomes irrevers- 
ible within 15 to 30 min. Thus, thrombolytic therapy cannot 
be administered early enough to abort acute myocardial 
infarction, considering the abrupt onset of total ischemia in 
most cases. The theoretical benefit of thrombolytic therapy 
is based instead on the hypothesis that myocardial ischemia 
due to thrombotic coronary occlusion may develop gradually 
over a period of several hours, so that reperfusion of an 
occluded coronary artery may result in myocardial salvage. 
Experimental studies of coronary occlusion. Several rele- 
vant experimental studies dealing with coronary occlusion 
have been reported. Schaper (2) showed that the principal 
mechanism protecting the myocardium is the flow from 
coronary collateral vessels. No myocardial salvage can be 
demonstrated in rats, rabbits or pigs, but in dogs collateral 
flow plays an important role in containing myocardial dam- 
age. The often quoted study in dogs by Reimer et al. (3) 
presents the “wa\e front theory,” a sequential development 
of ischemic cell death over a period of hours. Other studies 
(4,5) show, however, that infarcts produced by coronary 
occlusion in dogs are completed within 2 or 3 h. A critical 
review of the concept of the potentially salvageable “border 
zone” by Hearse and Yellon (6) leaves reasonable doubt 
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regarding the size or even the existence of such a zone. 
Furthermore, the results of such experimental studies should 
be extrapolated to myocardial infarction in humans with 
great caution. First, in view of the differences in coronary 
anatomy and responses among nonhuman mammals, it is 
possible that the results of experiments in dogs have limited 
relevance in humans. Second, the occlusion of a coronary 
artery in the presence of a normal coronary circulation may 
not be equivalent to occlusion in chronic coronary disease. 
Clinical evidence of myocardial salvage. In view of the 
limited amount of the experimental evidence, it is essential 
to seek support for thrombolytic therapy from clinical ob- 
servations. Some observations appear to support at least 
short-term benefits from thrombolysis: for example, relief of 
chest pain has been frequently observed. Decrease of ST 
segment elevation in the electrocardiogram may also occur. 
These observations, however, do not constitute evidence of 
the reduction of infarct size. Present methods of estimating 
infarct size are neither reliable nor accurate enough to make 
possible a controlled study. 
Thus, the cardiuc effects of thromholytic therapy have to 
tw drmonstrrrted indirect/y by intervention trials dealing 
with the clinical outcome of this therapy. When clinical trials 
aimed at evaluation of therapy are based on uncertain 
theoretical foundations, it is essential to define clearly the 
potential benefit and the expected outcome of the tested 
intervention. Myocardial salvage resulting in reduction of 
infarct size is expected to have its principal effect on left 
ventricular function. Treated patients, compared with con- 
trol subjects, should show a lower incidence of severe 
cardiac failure and cardiogenic shock and, both in the acute 
stage. and during the first postinfarction year, should have a 
lower rate of death due to pump failure or ventricular 
fibrillation. Inasmuch as the timing of treatment is of critical 
importance, there should be a strong time-benefit relation. If 
all these clinical consequences of infarct size reduction are 
clearly and consistently demonstruted in clinical trials, then 
the plausibility of the proposed rationale for thrombolysis is 
enhanced. However, if the expected consequences are not 
encountered, then the hypothesis on which the rationale for 
treatment is based may need reconsideration. 
Results of recent intervention trials of thrombolytic ther- 
apy. A large number of intervention trials have been per- 
formed evaluating the outcome of thrombolytic therapy. 
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Most of these trials elected as their expected outcome, the 
reduction of mortality in treated patients; some dealt with 
improvement of left ventricular function. Streptokinase has 
been used as the thrombolytic agent in most of the trials thus 
far completed. 
Yussef et al. (7) reviewed the results of 33 trials. Nine 
trials evaluated intracoronary use of streptokinase. In none 
of these nine was there a statistically significant difference in 
mortality between treated and control patients. Pooled re- 
sults showed a slight trend in favor of treated patients; 
however, it was below the level of statistical significance. Of 
the 24 trials dealing with intravenous administration of 
streptokinase, 19 failed to show significant difference, 
whereas in 5, a statistically significant reduction of mortality 
was demonstrated. By pooling data from this group, a 
significant p value for the entire group could be demon- 
strated. Pooling data from several trials is statistically per- 
missible. However, the small number of patients in the 
individual trials and the nonhomogeneity of the tested pop- 
ulations (mortality of untreated patients ranged from 8% to 
29%) made such data a demonstration of a marginal trend 
rather than acceptable results. The significance of this anal- 
ysis is further seriously weakened by the fact that the pooled 
mortality of control patients was 19% and that of treated 
patients 15%; thus, those who were thought to have bene- 
fitted from thrombolysis had a higher mortality than the 
accepted average figures. 
Results of two randomized trials dealing with a sufji- 
ciently large number of patients to provide high reliability 
are now available: the Italian trial (GISSI) (89) and the 
international trial (ISIS-2) (10). Results of a major trial of 
intravenous streptokinase performed in Italy (GISSI), in 
which 11,806 patients with acute myocardial infarction were 
randomized, were reported in 1986. The target point of this 
trial was the effect of thrombolysis on mortality with the 
intervention taking place 1 to 12 h after the assumed onset of 
infarction. The overall results show a lower hospital mortal- 
ity in the treated group (13.0% versus 10.7%; p = 0.0002). 
Analysis of the data according to time of administration of 
streptokinase showed that the greatest benefit was observed 
for 0 to 1 h, lesser benefit up to 6 h and no benefit after 6 h. 
Subgroup analysis indicates that streptokinase is effec- 
tive only in certain kinds of patients with acute myocardial 
infarction. Three subsets were identified in which there was 
a highly significant difference in mortality favoring treated 
patients: patients with anterior infarction, those with a first 
infarction and those ~65 years of age. When the data are 
analyzed according to left ventricular function, the GISSI 
trial demonstrated reduced mortality of treated patients with 
normal or mildly impaired left ventricular function (Killip 
classes I and II), but not for the high risk subset with 
severely compromised function (Killip class III [severe heart 
failure] or class IV [cardiogenic shock]). Furthermore, the 
incidence of cardiogenic shock was not affected by treatment 
(228 control patients, 248 treated patients). The separately 
reported l-year mortality of GISSI patients (9) showed that 
posthospital mortality of treated survivors was similar to 
that of control patients. 
The final report of the second large randomized trial of 
thrombolytic therapy (ISIS-2) appeared in 1988 (10). In it, 
17,187 patients with suspected acute myocardial infarction, 
admitted within 24 h after symptom onset, were randomized 
with placebo control into four treatment groups, streptoki- 
nase infusion, oral aspirin administration, treatment with 
both of these agents and placebo control. The target of the 
study was 5 week survival. Streptokinase and aspirin re- 
duced mortality almost to the same extent (12% versus 9.2% 
and 11.8% versus 9.4%, respectively); use of both agents 
produced a higher rate of survival (13.2% versus 8.0%). 
Analysis of benefits according to the time of treatment 
showed that most benefit occurred during the 1st h with a 
slight decrease during the following 3 h and a persistence of 
the benefit at a lower level during the 5 to 12 h period and the 
13 to 24 h period. 
Conclusions derived from the trials: is there myocardial 
salvage? Review of the findings of the two large trials from 
the perspective of the expected benefits supporting the 
theory postulating myocardial salvage as the result of throm- 
bolysis yields the following conclusions: The GISSI trial 
showed that 1) the expected reduction in 1st year mortality 
of survivors of acute myocardial infarction was not found; 2) 
the expected lowering of the incidence of cardiogenic shock 
was not present; 3) the expected reduction of mortality in 
patients with severe pump damage (Killip classes III and IV) 
was not present; and 4) only a weak time-benefit relation was 
found, favoring the 1st h and extending to 6 h. The ISIS-2 
trial provided no analysis of subsets of acute myocardial 
infarction, hence comparable findings are not available. 
However, indirect strong evidence against the myocardial 
salvage theory is suggested by the fact that aspirin-a 
platelet antiaggregant substance-exerts comparable benefit 
to thrombolysis. Furthermore, the extension of benefits up 
to 24 h after the initial attack is a further argument against 
the theory in question. 
The interpretation of intervention trials dealing with 
benefit of thrombolysis in acute myocardial infarction, tar- 
geted at the detection of reduced mortality, presents consid- 
erable difficulties. The large number of variables in patients 
with acute myocardial infarction, which include size, loca- 
tion and depth (transmural versus subendocardial) of the 
infarct, the state of the heart before the attack, disease in 
other coronary branches or presence of collateral vessels, 
produces a population with widely different prognoses. 
Randomization of this mixed population requires a very 
large number of subjects to give credible answers, estimated 
by Norris and White (11) to be at a level of 15,000 to 20,000 
patients. The GISSI and ISIS trials are thus the only ones 
approaching these numbers. Furthermore, their reliability is 
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confirmed by the almost identical mortality figure for un- 
treated patients ( 12.0% versus 13.0%), which is well within 
the generally accepted range of hospital mortality. 
The trials aimed at demonstrating improved ejection 
fraction (12-16) show contradictory results and are based on 
insufficient numbers of cases to account for the wide vari- 
ability of responses. They may be interpreted as merely 
suggesting the possibility that slightly better left ventricular 
performance may be found in treated patients. 
Thus, one finds that a theory of infarct size reduction 
produced by thrombolytic reperfusion of the occluded cor- 
onary artery, based on questionable experimental founda- 
tion, has no support in the two clinical trials considered to be 
decisive. Inasmuch as this theory has to be questioned. an 
alternative hypothesis that could explain the observed ben- 
efits of thrombolytic therapy should be considered. 
Alternative hypothesis to explain benefits of thrombolytic 
therapy. In developing such a hypothesis, it is necessary to 
consider current concepts of the pathogenesis of acute 
coronary syndromes. There is now convincing evidence 
(17,18) that thrombus formation is an important factor in all 
syndromes that are considered a spectrum: unstable angina 
pectoris, lesser coronary syndromes, subendocardial and 
nontransmural myocardial infarction and Q wave (“transmu- 
ral”) infarction. All these are presumed to be initiated by a 
rupture of an atherosclerotic plaque, which sets into motion 
platelet aggregation and thrombus formation. It has been 
postulated that the consequence of such a “coronary acci- 
dent” depends on availability of collateral circulation and 
extent of the thrombotic process. This view is best summa- 
rized by Ambrose et al. (18): “The variable clinical presen- 
tations of patients with total occlusion suggests that there are 
differences in the rate of development of total occlusion, the 
amount of collateral circulation, or both.” Q wave infarction 
represents the most serious coronary event and is consid- 
ered the result of a lack of available collateral vessels, and of 
complete occlusion of a major branch. It produces the most 
serious myocardial damage and accounts for most, if not all. 
cases presenting severe pump failure, cardiogenic shock and 
ventricular aneurysm. A recent pathologic study by Piek and 
Becker (19) demonstrated not only the paucity of collateral 
vessels in Q wave infarction, but the fact that the outer zone 
of dual blood supply, potentially salvageable in the presence 
of thrombotic occlusion, is very small. Non-Q wave infarc- 
tion results in less severe myocardial damage and may be 
associated with incomplete thrombotic occlusion, delayed 
thrombus formation and higher incidence of spontaneous 
thrombolysis (20,2 I). Lesser coronary syndromes involve 
presumably still better collateral circulation and more rapid 
appearance and disappearance of coronary thrombi. 
These considerutions suggest that Q wave infarction is 
least likely to henejit from thrombolysis, that is, with total 
occlusion of a large coronary branch, absence of collateral 
vessels and small lateral zone, the probability is great that 
irreversible ischemia will develop within a short time and 
reperfusion cannot be accomplished early enough to salvage 
myocardium. 
Conclusions. Thus. the findings of the two major inter- 
vention trials are best explained by the hypothesis that, 
contrary to the generally accepted view, Q wave infarction 
may not be benefited by thrombolytic therapy, but rather, 
non-Q wave infarction and other less severe coronary syn- 
dromes are more likely favorably influenced by it. This 
hypothesis would best explain the finding that thrombolytic 
substances and aspirin produce similar reduction of mortal- 
ity and possibly act synergistically, as well as the persistence 
of the effect for 24 h. The exact mechanism of the action 
needs further investigation. Protection from formation and 
propagation of thrombi and its consequences may account 
for the beneficial effects of thrombolysis. Myocardial salvage 
may play a less important role in explaining the benefits 
derived from this therapy. 
Direct confirmation of the proposed hypothesis is not 
now available, inasmuch as in none of the major trials were 
benefits in patients with Q wave infarction compared with 
those of other patients with acute coronary syndromes. 
Nevertheless, the results of the ISIS-2 trial and reinterpre- 
tation of some of the findings of the GISSI trial may call for 
rethinking of the strategies regarding thrombolytic therapy. 
The only benefit of thromhol~vir therapy demonstrated 
beyond reasonable doubt is a reduction of mortality in 
treated patients, by 2.3% (GISSI) and 2.8% (ISIS). Thus, 
patients who are administered a thrombolytic substance 
have a >97% probability that they will derive no benefit from 
the treatment, yet are subjected to a small, though not 
negligible risk. The risk-benefit relation could conceivably 
be greatly improved if subsets more likely to benefit from 
thrombolysis are identified, and if the relation between 
thrombolytic and antiplatelet therapy is clarified. Already, 
the authors reporting the results of the ISIS-2 trial suggest 
that thrombolytic therapy could be delayed until the patient 
is in the coronary care unit, rather than administering it as 
early as possible. At present, most research energy is spent 
on development and testing of new thrombolytic drugs. It is 
clear that an investigation of the mechanisms of the benefit 
from thrombolytic therapy deserves a higher priority. 
I am indebted to Rodger Shepherd. MD for statistical consultation and review 
of the manuscript. 
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